Metrika članka

  • citati u SCindeksu: 0
  • citati u Google Scholaru:[=>]
  • posete u prethodnih 30 dana:4
  • preuzimanja u prethodnih 30 dana:2
članak: 1 od 1  
Medicinski časopis
2017, vol. 51, br. 4, str. 131-135
jezik rada: engleski
vrsta rada: pregledni članak
doi:10.5937/mckg51-16428


Savremeni pristup u lečenju retinopatije prematuriteta
aClinical Centre Kragujevac, Clinic of Ophthalmology, Kragujevac + University of Kragujevac, Faculty of Medical Sciences, Department of Ophthalmology, Kragujevac
bUniverzitet u Kragujevcu, Medicinski fakultet

e-adresa: tvoja.tanja@yahoo.com

Sažetak

Retinopatija prematuriteta je proliferativna retinopatija koja se javlja kod prevremeno rođene dece. Ona još uvek predstavlja vodeći uzrok preventabilnog slepila dečijeg doba širom sveta. Cilj ovog rada je da prezentuje terapijske mogućnosti retinopatije prematuritete. Trenutni zlatni standard u lečenju je laserska fotokoagulacija avaskularne retine radi smanjenja nastale hipoksije. Širenjem naših saznanja o patogenezi retinopatije prematuritete, kao i saznanja o efikasnosti i komplikacijama laserske terapije, pojavljuju se nove terapijske mogućnosti (intravitrealna aplikacija anti-VEGF faktora, genska terapija i primena suplemenata). Radi izbegavanja gubitka vidne funkcije prematurusa izazvanog retinopatijom prematuritetom, prvi izbor predstavlja skrining prevremeno rođene dece.

Ključne reči

Reference

Akçakaya, A.A., Yaylali, S.A., Erbil, H.H., Sadigov, F., Aybar, A., Aydin, N., Akçay, G., Acar, H., Mesçi, C., Yetik, H. (2011) Screening for Retinopathy of Prematurity in a Tertiary Hospital in Istanbul: Incidence and Risk Factors. Journal of Pediatric Ophthalmology & Strabismus, 49(1): 21-25
Altinsoy, H.I., Mutlu, F.M., Güngör, R., Sarici, S. Ü. (2010) Combination of Laser Photocoagulation and Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity. Ophthalmic Surgery, Lasers, and Imaging, 1-5
Amadio, M., Govoni, S., Pascale, A. (2016) Targeting VEGF in eye neovascularization: What's new?. Pharmacological Research, 103: 253-269
Autrata, R., Krejčířová, I., Šenková, K., Holoušová, M., Doležel, Z., Borek, I. (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. European Journal of Ophthalmology, 22(5): 687-694
Azad, R. (2011) Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons′ in Hamlet′s dilemma?. Indian Journal of Ophthalmology, 59(6): 421
Bancalari, A., Schade, R., Muñoz, T., Lazcano, C., Parada, R., Peña, R. (2016) Oral propranolol in early stages of retinopathy of prematurity. Journal of Perinatal Medicine, 44(5):
Bhola, R., Purkiss, T., Hunter, S., Stewart, D., Rychwalski, P.J. (2009) Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity. Journal of American Association for Pediatric Ophthalmology and Strabismus, 13(5): 450-453
Castellanos, M.A.M., Schwartz, S., García-Aguirre, G., Quiroz-Mercado, H. (2012) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. British Journal of Ophthalmology, 97(7): 816-819
Chen, J., Connor, K.M., Aderman, C.M., Willett, K.L., Aspegren, O.P., Smith, L.E. H. (2009) Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative Retinopathy. Investigative Opthalmology & Visual Science, 50(3): 1329
Chowers, I. (2001) Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity. British Journal of Ophthalmology, 85(8): 991-995
Chung, E.J., Kim, J.H., Ahn, H.S., Koh, H.J. (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity. Graefe's Archive for Clinical and Experimental Ophthalmology, 245(11): 1727-1730
Colakoğlu, O., Taşkiran, B., Colakoğlu, G., i dr. (2007) Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk J Gastroenterol, 18: 245-9
de Graaf, M., Breur, J.M.P.J., Raphaël, M.F., Vos, M., Breugem, C.C., Pasmans, S.G.M.A. (2011) Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infants. Journal of the American Academy of Dermatology, 65(2): 320-327
Filippi, L., Cavallaro, G., Fiorini, P., Daniotti, M., Benedetti, V., Cristofori, G., Araimo, G., Ramenghi, L., la Torre, A., Fortunato, P., Pollazzi, L., la Marca, G., Malvagia, S., Bagnoli, P. (2010) Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatrics, 10(1): 83
Gilbert, C., Foster, A. (2001) Childhood blindness in the context of VISION 2020-the right to sight. Bull World Health Organ, 79: 227-32
Gole, A.G., Ells, A.L., Katz, X., i dr. (2005) The international classification of retinopathy of prematurity revisited. Arch Ophtalmol, 123: 991-9
Greenblatt, D.J., Koch-Weser, J. (1973) Adverse reactions to propranolol in hospitalized medical patients: A report from the Boston Collaborative Drug Surveillance Program. American Heart Journal, 86(4): 478-484
Hård, A., Hellström, A. (2011) On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatrica, 100(8): 1063-1065
Heckmann, M. (2008) Pathogenesis of retinopathy of prematurity. Der Ophthalmologe, 105(12): 1101-1107
Hoogerwerf, A., Schalij-Delfos, N.E., van Schooneveld, M.J., Termote, J.U.M. (2010) Incidence of Retinopathy of Prematurity over the Last Decade in the Central Netherlands. Neonatology, 98(2): 137-142
Hunt, S. (2007) Increased dietary intake of omega-3-PuFA reduces pathological retinal angiogenesis. Ophtalmologe, 104: 727-9
Ioannou, P.A., Vadolas, J. (2006) Human Gene Therapy: Risks and Safety Considerations. Chichester, UK: Wiley
Johnson, L., Bowen, F.W., Abbasi, A., i dr. (1985) Relationship of prolonged pharmacologic serum levels of vitamin E to incidence of sepsis and necrotizing enterocolitis in infants with birth weight 1, 500 grams or less. Pediatrics, 75, 619-638
Johnson, L., Quinn, G.E., Abbasi, S., Otis, C., Goldstein, D., Sacks, L., Porat, R., Fong, E., Delivoria-Papadopoulos, M., Peckham, G., Schaffer, D.B., Bowen, F.W. (1989) Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: A controlled clinical trial. Journal of Pediatrics, 114(5): 827-838
Kanski, J.J. (2003) Clinical ophthalmology. Elsevier, 473-478; 5th ed
Landers, M.B. (1992) Treatment of Retinopathy of Prematurity With Argon Laser Photocoagulation. Archives of Ophthalmology, 110(1): 44
Lee, J.Y., Chae, J.B., Yang, S.J., Yoon, Y.H., Kim, J. (2010) Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefe's Archive for Clinical and Experimental Ophthalmology, 248(9): 1257-1262
Löfqvist, C. (2006) Longitudinal Postnatal Weight and Insulin-like Growth Factor I Measurements in the Prediction of Retinopathy of Prematurity. Archives of Ophthalmology, 124(12): 1711
Löfqvist, C., Niklasson, A., Engström, E., Friberg, L.E., Camacho-Hübner, C., Ley, D., Borg, J., Smith, L.E.H., Hellström, A. (2009) A Pharmacokinetic and Dosing Study of Intravenous Insulin-Like Growth Factor-I and IGF-Binding Protein-3 Complex to Preterm Infants. Pediatric Research, 65(5): 574-579
Mintz-Hittner, H.A., Kuffel, R.R. (2008) Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone i or posterior zone ii. Retina, 28(6): 831-838
Mintz-Hittner, H.A., Kennedy, K.A., Chuang, A.Z. (2011) Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity. New England Journal of Medicine, 364(7): 603-615
Mutlu, F.M., Sarici, S.Ü. (2007) Retinopathy of prematurity: incidence and risk factors. Expert Review of Ophthalmology, 2(2): 267-274
Mutlu, F.M., Altinsoy, H. I., Mumcuoglu, T., Kerimoglu, H., Kiliç, S., Kul, M., Sarici, S. Ü., Alpay, F. (2008) Screening for Retinopathy of Prematurity in a Tertiary Care Newborn Unit in Turkey: Frequency, Outcomes, and Risk Factor Analysis. Journal of Pediatric Ophthalmology & Strabismus, 45(5): 291-298
Nuzzi, R., Tridico, F. (2015) Complications of intravitreal anti-VEGF drugs: a report on our personal experience. J Clin Exp Ophthalmol, 6: 448
Palmer, E.A., Flynn, J.T., Hardy, R.J., i dr. (1991) Incidence and early course of retinopathy of prematurity: The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology, 98: 1628-40
Phan, M.H., Nguyen, P.N., Reynolds, J.D. (2003) Incidence and severity of retinopathy of prematurity in Vietnam, a developing middle-income country. Journal of pediatric ophthalmology and strabismus, 40(4): 208-12
Ramsey, D.J., Haddock, L.J., Young, L.H., Eliott, D. (2014) Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway. Seminars in Ophthalmology, 29(5-6): 263-275
Serrano, M.L., Romero, A., Cendales, R., Sánchez-Gómez, M., Bravo, M.M. (2006) Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica, 26: 258-68
Smith, L.E., Hard, A., Hellström, A. (2013) The Biology of Retinopathy of Prematurity. Clinics in Perinatology, 40(2): 201-214
Smith, L.E. H., Shen, W., Perruzzi, C., Soker, S., Kinose, F., Xu, X., Robinson, G., Driver, S., Bischoff, J., Zhang, B., Schaeffer, J.M., Senger, D.R. (1999) Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nature Medicine, 5(12): 1390-1395
Smith, L.E. (2003) Pathogenesis of retinopathy of prematurity. Seminars in Neonatology, 8(6): 469-473
Sonmez, K., Drenser, K.A., Capone, A., Trese, M.T. (2008) Vitreous Levels of Stromal Cell-Derived Factor 1 and Vascular Endothelial Growth Factor in Patients with Retinopathy of Prematurity. Ophthalmology, 115(6): 1065-1070.e1
Stahl, A., Sapieha, P., Connor, K. M., SanGiovanni, J. P., Chen, J., Aderman, C. M., Willett, K. L., Krah, N. M., Dennison, R. J., Seaward, M. R., Guerin, K. I., Hua, J., Smith, L. E. H. (2010) Short Communication: PPAR  Mediates a Direct Antiangiogenic Effect of  3-PUFAs in Proliferative Retinopathy. Circulation Research, 107(4): 495-500
Travassos, A., Teixeira, S., Ferreira, P., i dr. (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Laser Imag, 38: 233-7
Young, T.L., Anthony, D.C., Pierce, E., Foley, E., Smith, L.E.H. (1997) Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. Journal of American Association for Pediatric Ophthalmology and Strabismus, 1(2): 105-110